stockrowRhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
Follow RYTM
Alert me
Rhythm Pharmaceuticals, Inc. (RYTM) EBITDA
Rhythm Pharmaceuticals, Inc.'s EBITDA for fiscal 2025 was −$190.7M, compared with −$263.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$186.2M. Over the past ten years it has ranged from −$263.9M (fiscal 2024) to −$10.6M (fiscal 2015); the current reading is higher than 18% of that period. Rhythm Pharmaceuticals, Inc. ranks 504th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$190.7M | — |
| FY2024 | −$263.9M | — |
| FY2023 | −$182.6M | — |
| FY2022 | −$177.5M | — |
| FY2021 | −$168.9M | — |
| FY2020 | −$135.9M | — |
| FY2019 | −$145.2M | — |
| FY2018 | −$78.0M | — |
| FY2017 | −$32.2M | — |
| FY2016 | −$25.8M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$39.0M | — |
| Jun 2026 | −$48.3M | — |
| Mar 2026 | −$52.1M | — |
| Dec 2025 | −$46.8M | — |
| 36 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | $108.8M |
| AXSM Axsome Therapeutics, Inc. compare | −$139.8M |
| ORKA Oruka Therapeutics, Inc. compare | −$158.0M |
| RYTM Rhythm Pharmaceuticals, Inc. | −$186.2M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$204.6M |
| ABVX Abivax SA Sponsored ADR compare | −$338.0M |
| PRAX Praxis Precision Medicines, Inc. compare | −$380.8M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$579.9M |
| CYTK Cytokinetics, Incorporated compare | −$694.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on RYTM
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement